Insider Buying: Elanco Animal Health (NYSE:ELAN) Insider Acquires 4,911 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Rajeev Modi bought 4,911 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were purchased at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Elanco Animal Health Stock Down 0.8%

NYSE ELAN traded down $0.16 on Tuesday, reaching $19.78. 7,919,678 shares of the stock traded hands, compared to its average volume of 5,317,265. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The company has a fifty day moving average price of $23.23 and a 200-day moving average price of $23.33. The company has a market cap of $9.88 billion, a price-to-earnings ratio of -39.55, a PEG ratio of 2.14 and a beta of 1.69. Elanco Animal Health Incorporated has a 12 month low of $12.40 and a 12 month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same period in the previous year, the company posted $0.37 EPS. Elanco Animal Health’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 1.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ELAN. UBS Group AG grew its stake in Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after buying an additional 5,961,457 shares during the last quarter. Sei Investments Co. grew its stake in Elanco Animal Health by 737.5% during the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after buying an additional 4,975,721 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Elanco Animal Health by 11.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Invesco Ltd. grew its stake in Elanco Animal Health by 336.0% during the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock worth $108,376,000 after buying an additional 3,690,735 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in Elanco Animal Health during the 1st quarter worth $66,390,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ELAN has been the topic of a number of analyst reports. Citigroup lifted their price target on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. KeyCorp lifted their price target on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, JPMorgan Chase & Co. lifted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $28.20.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.